Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Imuldosa®, a biosimilar to Stelara®, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), paving the way for its authorization in Europe. Developed by Accord ...

The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...